In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.
In 1Q18, Amgen’s (AMGN) Kyprolis revenue grew 17% YoY (year-over-year) to $222 million from $190 million, primarily due to higher unit demand in international markets.
In 4Q17, Novartis’s (NVS) Gleevec generated revenues of $448 million, which reflected a ~41% decline on year-over-year (or YoY) basis and 1% growth quarter-over-quarter.
In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline year-over-year.
In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).
In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.
In 3Q17, Johnson & Johnson’s (JNJ) Velcade generated revenues of $273 million, a ~10% decline on a year-over-year (or YoY) basis and a 6% decline quarter-over-quarter.
Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.
Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.
In 3Q17, Bristol-Myers Squibb’s (BMY) Sprycel generated revenues of $509 million, an 8% increase on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.
In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which with ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter).
Blincyto’s revenue trends In 2Q17, Amgen’s (AMGN) Blincyto generated revenues of ~$43 million, which represented ~43% growth on a YoY (year-over-year) basis. Blincyto (blinatumomab) is an injection for the treatment of adults and children with relapsed or refractory B-cell precursor ALL (acute lymphoblastic leukemia). For more on Blincyto and its revenue prospects, please refer to […]
Kyprolis’s revenue trends In 2Q17, Amgen’s (AMGN) Kyprolis generated revenues of ~$211 million, which reflected ~23% growth on a YoY (year-over-year) basis and ~11% growth QoQ (quarter-over-quarter). In 2Q17, Kyprolis witnessed a ~20% volume growth QoQ, and its launch in international markets contributed heavily to the company’s overall YoY revenue growth. In 2Q17, in the US, Kyprolis […]
In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.
In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.
Gastrointestinal franchise prescriptions In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) drugs Xifaxan, Uceris, Apris, and Relistor reported solid year-over-year (or YoY) growth in prescriptions, of around 18%, 6%, 4%, and 1%, respectively. Relistor growth trends Since the launch of the oral version of Relistor in 4Q16, the drug has witnessed a 13% rise in total […]
Gastrointestinal business In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) franchise saw its revenue fall due to the loss of patent protection for drugs Zegerid and Glumetza in the US market. Furthermore, the authorized generic version of Zegerid was transferred from Valeant’s Branded Rx segment to the Diversified Products segment. However, these negative trends were […]
Teva Pharmaceutical’s (TEVA) strategy of selectively focusing on certain countries has enabled it to see double-digit organic growth in the growth markets.
The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.
The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.
In fiscal 2015, Lialda added $684.4 million to Shire’s (SHPG) top line, reflecting an 8% annual increase in sales. This was supported by a 10% rise in prescription volume.
The Voya Japan TOPIX Index Portfolio – Class A (IJIAX) fell 0.9% in December 2015 from the previous month. In the three- and six-month periods ended December 31, the fund has risen 7.3% and fallen 4.0%, respectively.
BIAJX fell 3.7% in December 2015 from the previous month. In the three-month and six-month periods ended December 31, 2015, the fund has risen 8.3% and fallen 6.4%, respectively.
Aside from the risky generic pharmaceutical industry, Mylan faces company-specific business risks like country risk, foreign exchange risk, and M&A risk.
Headquartered in the UK, Mylan is one of the biggest players in the generic pharmaceutical industry. It was founded by Milan Puskar and Don Panoj in 1961.
On November 30, 2015, Bristol-Myers Squibb (BMY) and AbbVie (ABBV) announced that the FDA has approved Empliciti for treatment of patients with multiple myeloma.
Based on the success of its clinical trial and its superior clinical profile, Takeda’s Ninlaro is expected to prove a tough competitor to other MM drugs.
Brown Advisory-WMC Japan Alpha Opportunities Fund doesn’t target a specific segment by market capitalization. Instead, it intends to be benchmark agnostic.
Performance evaluation The Brown Advisory-WMC Japan Alpha Opportunities Fund (BIAJX) fell by 6.7% in September 2015 from the previous month. In the three- and six-month periods ending September 30, the fund fell by 13.5% and 7.7%, respectively. However, in the YTD (year-to-date) period, the fund was up by 2.9%. For all periods mentioned above except […]
According to projections by Novo Nordisk (NVO), targeting the obesity market by pharmaceutical companies is about 4–5 DKK (Danish krone currency) in value.
